New Educational Webinar Sponsored by Cenduit LLC Presents Case Study on Best Practices in Using IRT Systems to Meet the Challenge of Rare Disease Clinical Trials
Subject matter experts from Washington University School of Medicine and Cenduit to describe patient-centric IRT delivery in a complex Alzheimer’s study and take live questions in free webinar moderated by Applied Clinical Trials
March 20, 2018 – Durham NC – Subject matter experts from Washington University School of Medicine and Cenduit LLC will join Applied Clinical Trials to discuss best practices for leveraging IRT (interactive response technology) systems to conduct rare disease clinical trials in a free educational webinar “How Technology Meets the Challenge of a Rare Disease Population” on March 28. The webinar is designed for clinical trial and IRT decision-makers: Clinical Operations and Clinical Supply Directors, CROs, and Sponsors.
Webinar presenters will discuss a case study on patient-centric IRT delivery in a complex Alzheimer’s research study, evaluating multiple therapies from several pharma companies. They will describe how using IRT to create site-less visits both reduced patient burden and increased retention by bringing the trial directly to patients, and eliminated geographic barriers.
Webinar: Technology Meets the Challenge of a Rare Disease Population
Date: Wednesday, March 28, 2018
Time: 8am PDT | 11am EDT | 4pm BST |5pm CEST
Moderator: Lisa Henderson, Editorial Director, Applied Clinical Trials
Presenters:
- Susan Mills, Associate Director of Research for Clinical Trial Operations within the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), Washington University in St. Louis School of Medicine
- Andrew Rohrbaugh, Director, Client Delivery, Cenduit LLC
The World Health Organization (WHO) defines a rare disease as one with a frequency of less than 6.5-10 per 10,000 people. There are approximately 7,000 rare diseases that affect more than 300 million people worldwide. Clinical trials are the only potential treatment option for many patients, but rare disease trials face challenges in finding, engaging and retaining patients. In this webinar, participants will learn:
- How Agile IRT was implemented in a complex adaptive trial for Alzheimer's research
- How to facilitate in-home drug delivery in a complex, multi-drug platform trial
- The impact of maintaining genetic blinding for trial participants, in combination with a minimization algorithm for a rare disease population
- Providing adequate safety and dosing controls at multiple levels
- How IRT adapted to these challenges while incorporating a true direct-to-patient model and enabled time and cost savings
About the Presenters
Susan Mills has over 20 years of experience managing and directing global clinical trials over a broad therapeutic range of programs, including Phase II-IV trials contributing to approvals of NDAs, ANDAs and BLAs. After a career at CROs and pharma companies Mills has spent the past six years in academia, launching the first-ever secondary prevention trial in Alzheimer’s disease, researching several therapies from multiple companies to target the prevention or delay of a rare form of inherited Alzheimer’s disease afflicting individuals from their 30s to 50s. This trial is a public-private partnership including multiple pharma partners, the US NIH, patient advocacy groups including the Alzheimer’s Association, and universities and hospitals across 17 countries. For more information on the DIAN-TU trial visit www.dian.wustl.edu.
Andrew Rohrbaugh has nearly 10 years of industry experience including project and account management of IRT, eSource, eCOA and connected devices. Andrew also has extensive expertise in implementing enterprise-level solutions, focused on standardization within unique customer needs. Prior to Cenduit he worked in the asset and investment management industries, servicing a wide variety of client-facing initiatives.
Lisa Henderson has over 20 years of experience in business-to-business publishing, covering a variety of industries including clinical trials, managed healthcare and information technology. In addition to her own educational and thought-provoking writing and speaking engagements Henderson leads teams of experienced journalists in producing content that stimulates discussion about how to move beyond the status quo.
About Cenduit LLC
Cenduit enables clinical trial sponsors and CROs to safely, quickly and economically deliver new drugs and therapies to help save and improve lives. As the world leader in IRT systems, Cenduit offers customers consistently innovated rapid study startup software, clinical supply chain intelligence, clinical operations expertise and customer-centric CORE teams. With 500+ experts throughout the US, Europe and Asia, Cenduit helps customers manage clinical trials in over 100 countries, interacting with more than 600,000 patients at over 32,000 sites. Learn how Cenduit's experts can ensure your study needs are met on time and within budget. Visit www.cenduit.com for more information.
Contact:
Shannon L. Davies, Shannon.lappindavies@cenduit.com, + 1 919-998-3393
Brenda Nashawaty, brenda@nashawaty.com, +1 617-688-3253